Physician profile
Shane D Gagon
NPI 1508951328
$5,760.83
in general payments reported to CMS, 2019-2025
54 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $682 · 2021: $909 · 2022: $759 · 2023: $841 · 2024: $781 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,969 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.22 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,158.08 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $912.74 | 2021-2025 | |
| Pfizer INC. | $331.87 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $327.08 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $272.69 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.21 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $230.64 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $220.66 | 2020-2023 | Jardiance, Mounjaro, Emgality |
| Xeris Pharmaceuticals, INC. | $186.54 | 2021-2025 | Gvoke Hypopen, Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $139.89 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $120.50 | 2021-2025 | Qelbree |
| Amgen INC. | $104.02 | 2019-2024 | Evenity, Prolia |
| Amneal Pharmaceuticals LLC | $101.42 | 2021-2023 | Rytary |
| Sunovion Pharmaceuticals INC. | $72.10 | 2019-2021 | |
| Glaxosmithkline, LLC. | $70.90 | 2020-2021 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Gagon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.